SUMMARY
Over the last decades, we have witnessed tremendous advances in the management of patients with multiple myeloma (MM). Not surprisingly, also the 2022 annual meeting of the American Society of Hematology (ASH) featured a wide range of abstracts dedicated to this plasma cell disorder. This article will discuss some of the most important MM related abstracts presented at this years’ meeting, including promising data generated with bispecific antibodies and CAR-T cell therapy and results of clinical trials evaluating ‘curative strategies’ in patients with high-risk smoldering multiple myeloma (SMM). In addition, this summary discusses someinteresting observations from the Icelandic iSTOPMM initiative and touches upon two innovative techniques to assess minimal residual disease (MRD) on peripheral blood in patients with MM. Finally, results of a study assessing a dexamethasone-sparing treatment regimen in frail patients with newly diagnosed MM (NDMM) will be addressed.
(BELG J HEMATOL 2023;14(1):19–25)
